GO
Loading...

FDA

More

  • Texas Oilman Pleads Guilty in Oil-for-Food Scandal Monday, 1 Oct 2007 | 11:24 AM ET
    Oscar Wyatt

    Texas oilman Oscar Wyatt pleaded guilty Monday to conspiracy to commit wire fraud, one of five counts against him for his role in the U.N. oil-for-food scandal.

  • Jets Fan Sues Patriots for $184 Million Sunday, 30 Sep 2007 | 12:51 PM ET

    A New York Jets season-ticket holder filed a class-action lawsuit Friday against the New England Patriots and coach Bill Belichick for "deceiving customers."

  • Dendreon's Provenge: The Latest On Cancer Drug Friday, 28 Sep 2007 | 9:34 AM ET
    dendreon_logo_new.jpg

    Everyone's favorite biotech--investors seem to either love it or hate it--was one of the presenters this morning at the UBS Global Life Sciences Conference in New York City. CEO Dr. Mitchell Gold once again did the honors. Generally speaking, biotech investors focus on milestones or key events in drug development.

  • Eli Lilly Receives New FDA Approval For Evista Friday, 14 Sep 2007 | 8:25 AM ET

    Drug developer Eli Lilly said Friday the Food and Drug Administration approved its osteoporosis drug Evista for use in reducing the risk of invasive breast cancer.

  • Medicare Urged to Reimburse More for Anemia Drugs Tuesday, 11 Sep 2007 | 12:36 PM ET

    Is the Senate coming to the rescue of patients, investors or both? That's the question being raised after the passage of a non-binding resolution telling Medicare to "immediately reconsider" its new policy to cut anemia drug use and reimbursement. Analysts are stunned by the move.

  • FDA Meetings And Latest On Biotech Front Tuesday, 11 Sep 2007 | 10:59 AM ET

    So, I thought I'd be spending today monitoring the webcast of the FDA Advisory Committees that are meeting to decide whether doctors should use less of the anemia drugs from Amgen and Johnson & Johnson to treat kidney dialysis patients.

  • Stocks Get a Lift, Street on Fed Watch Tuesday, 11 Sep 2007 | 8:53 AM ET

    Wall Street is counting down to next week's Fed meeting and not much else is influencing trading. Stocks are readying for a higher opening as investors wait for a speech from Fed Chairman Ben Bernanke later this morning and watch the action at OPEC.

  • FDA Warns on Boston Scientific Aortic Stent Trial Monday, 10 Sep 2007 | 6:40 AM ET

    U.S. health regulators charged Boston Scientific with inadequate record-keeping and reporting following the deaths of five patients implanted with an experimental device to treat a dangerous ballooning of the body's main artery.

  • Amylin's Byetta LAR: Wait Is On For Results Thursday, 6 Sep 2007 | 4:08 PM ET

    An update from the NewsMakers in Biotech conference in NYC on an item of intense interest. Amylin Pharmaceuticals just held a well-attended PowerPoint presentation followed by a very cramped breakout session. And pretty much the only thing investors and analysts wanted to talk about is Byetta LAR (long-acting release).

  • Merck Wins Reversal of Vioxx Class-Action Status Thursday, 6 Sep 2007 | 12:27 PM ET

    Merck said Thursday the New Jersey Supreme Court has reversed a lower court ruling that had granted nationwide class-action status to insurers seeking reimbursement for past spending on Vioxx, the drugmaker's withdrawn arthritis treatment.

  • Merck's AIDS Drug Gets FDA Staff Support Friday, 31 Aug 2007 | 9:45 AM ET

    Benefits of an experimental AIDS drug developed by Merck & Co appear to outweigh risks, according to U.S. Food and Drug Administration staff documents released Friday ahead of an advisory panel meeting.

  • Schering-Plough and Merck Tuesday said U.S. regulators had accepted the marketing application for their experimental allergy drug, which combines two widely used existing treatments into a single tablet.

  • prostate_cancer.jpg

    In case you hadn't heard September is Prostate Cancer Awareness Month. It's the #2 cancer killer of American men behind lung cancer. The American Cancer Society estimates nearly 220,000 men will be diagnosed with the disease this year. And as the emails coming into our inboxes indicate, it's going to be a busy month for those who are trying to get more money, research and drugs to help fight it.

  • Fired Wal-Mart Exec's Lawsuit Dismissed Thursday, 23 Aug 2007 | 4:39 AM ET

    A state judge in Michigan has sided with Wal-Mart Stores and dismissed a lawsuit by former marketing executive Julie Roehm over her firing, saying the case should be filed in Arkansas.

  • FDA Debate: Is Agency Really Doing Its Job? Tuesday, 21 Aug 2007 | 12:40 PM ET
    Dr.Andrew von Eschenbach

    In an editorial today, USA Today calls on the Food and Drug Administration to let dying patients get quicker, easier access to promising, potentially lifesaving or life-extending, developmental drugs. The paper argues that thousands of people in "dire circumstances" deserve "the chance to take a last-ditch gamble".

  • Shares of Dendreon rose Monday after the company said its breast cancer drug was effective in an early stage clinical trial.

  • Amgen's Full-Court Press Friday, 17 Aug 2007 | 5:37 PM ET

    On Amgen's conference call the other day regarding the biotech company's cutbacks, officials repeatedly stated that they think the federal government's new, restrictive guidelines for use and payment of Amgen's bread-and-butter anemia drugs will hurt patients and specifically, result in the need for more risky, old-fashioned blood transfusions to treat the condition.

  • Amgen Plans to Cut 12-14% of Staff, Lowers Guidance Wednesday, 15 Aug 2007 | 4:38 PM ET

    Biotechnology firm Amgen said after U.S. markets closed Wednesday that it will slash its employee base by between 12 and 14% in hopes of reducing its 2008 cost forecasts by $1 billion to $1.3 billion on a pre-tax basis.

  • Turning Up the Heat (Again) on the FDA Tuesday, 14 Aug 2007 | 3:08 PM ET
    FDA

    For the second time in two weeks, an op-ed item appears in The Wall Street Journal today calling out the FDA for its record on timely approval of cancer drugs.

  • Merck: As Stock Gets Upgrade Is Vioxx Coming Back? Monday, 6 Aug 2007 | 11:26 AM ET

    In very early trading MRK shares are rallying this morning on the wings of an upgrade at Cowen & Co. by analyst Steve Scala from Neutral to Outperform. He's been at a Neutral since a year and one month ago when the stock was sitting in the 30s. Today it's in the low 50s.